Post-operative Atrial Fibrillation Clinical Trial
Official title:
Division of Cardiology, Department of Internal Medicne, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
NCT number | NCT04993456 |
Other study ID # | TJ-CT-POAF |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 15, 2021 |
Est. completion date | July 15, 2024 |
Verified date | August 2021 |
Source | Tongji Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Post-operative atrial fibrillation (POAF) is one of the common complicaiton following cardiac surgery, occurring in approximately 20%-40% patients. Although POAF is associated with longer hospital stays, most POAF is short lived and resolves in the 2-4 days afer cardiac surgery. However, a recent meta-analysis showed significant increases in 1,5, and 10 year mortality in POAF patients (odds ratio:1.60, 2.60, 1.51;95% confidence intervals: 1.52 to 1.68, 2.00 to 3.38, 1.43 to 1.60;P <0.0001), the combined adjusted risk of death (16 studies, n =84,295) was also significantly increased in patients with POAF (hazard ratio: 1.25;95% confidence interval: 1.2-1.3;P < 0.0001). These data highlight the need to understand better the underlying mechanism of POAF. A latest research in Nature reported levels of circulating calcitonin (CT), which is the main risk factor for atrial fibrillation (AF). Global disruption of CT receptor signalling in mice causes atrial fibrosis and increases susceptibility to AF. Here we will explore the relationship between CT and POAF.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | July 15, 2024 |
Est. primary completion date | July 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - 1. Clinical diagnosis of no history of atrial fibrillation/flutter; - 2. Heart rate =50 beats/min; - 3. EF > 40%; - 4. No history of emergency cardiac surgery in our hospital; - 5. Participate voluntarily and sign the informed consent, and can accept the follow-up of more than 2 years. Exclusion Criteria: - 1. Atrial fibrillation/flutter; - 2. Left atrial diameter >5.5cm; - 3. Previous cardiac surgery or emergency surgery (<12h); - 4. Sick sinus node syndrome; - 5. Ventricular preexcitation or preexcitation syndrome; - 6. Second degree or above atrioventricular block; - 7.Myocardial infarction occurred within 7 days; - 8. Infection, sepsis, rheumatic or inflammatory diseases; - 9. Abnormal liver and kidney function (three times higher than the upper limit of normal); - 10. Uncontrolled hyperthyroidism, severe obstructive sleep apnea, and acute alcoholism; - 11. Any ischemic events (stroke or TIA) that occurred 180 days before the participant signed the informed consent, or any known unresolved complications from previous stroke/TIA;Thrombosis; - 12. Patients with other diseases requiring radiotherapy, chemotherapy and long-term hormone therapy; - 13. Patients' life expectancy makes it unlikely that follow-up will be completed; - 14. Participate in, or are expected to participate in, other clinical trials of any drugs, devices or biologics during the study period; - 15. Patients with contraindications to dynamic electrocardiogram; - 16. Patients who are unwilling or unable to fully comply with study procedures and follow-up. |
Country | Name | City | State |
---|---|---|---|
China | Tongji Hospital | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Tongji Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Thromboembolic stroke | Thromboembolic stroke | 2 years after cardiac surgery | |
Other | Serious bleeding events | Serious bleeding events | 2 years after cardiac surgery | |
Other | All-cause mortality | Cardiovascular, noncardiovascular or undetermined cause of death | 2 years after cardiac surgery | |
Other | Recurrence atrial fibrillaiton and readmission | Recurrence atrial fibrillaiton and readmission | 2 years after cardiac surgery | |
Primary | POAF lasting longer than 30 seconds during the first week after cardiac surgery | The incidence of atrial fibrillation lasting longer than 30 seconds during the first week after cardiac surgery | 2 years after cardiac surgery | |
Secondary | The hospitalization days | The length of stay after the cardiac surgery | 2 years after cardiac surgery | |
Secondary | Ventricular rate of the atrial fibrillation | Ventricular rate of atrial fibrillation after the cardiac surgery | 2 years after cardiac surgery | |
Secondary | Levels of serum calcitonin | Levels of serum calcitonin of atrial fibrillation after the cardiac surgery | 2 years after cardiac surgery | |
Secondary | Levels of serum procalcitonin | Levels of serum procalcitonin of atrial fibrillation after the cardiac surgery | 2 years after cardiac surgery | |
Secondary | Levels of serum hsCRP | Levels of serum hsCRP of atrial fibrillation after the cardiac surgery | 2 years after cardiac surgery | |
Secondary | Levels of serum cytokines(IL-1ß,IL-2R,IL-6,IL-8,IL-10,TNF-a) | Levels of serum cytokines(IL-1ß,IL-2R,IL-6,IL-8,IL-10,TNF-a) of atrial fibrillation after the cardiac surgery | 2 years after cardiac surgery | |
Secondary | Atrial fibrillation burden after cardiac surgery | Time and length of atrial fibrillation after cardiac surgery | lidan2014@tjh.tjmu.edu.cn |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05223725 -
Gene Therapy for Post-Operative Atrial Fibrillation
|
Phase 1 | |
Recruiting |
NCT06124937 -
Empagliflozin to Prevent Post-Operative Atrial Fibrillation
|
Phase 3 | |
Completed |
NCT03943927 -
Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery
|
N/A | |
Completed |
NCT03779841 -
Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)
|
Phase 2 | |
Completed |
NCT03525860 -
Acupuncture Treatment for Patients Who Develop Arrhythmias in the Post-Operative Cardio-Thoracic Setting
|
N/A | |
Completed |
NCT02701062 -
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
|
Phase 4 | |
Recruiting |
NCT02029534 -
Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)
|
Phase 4 |